Medicenna Establishes At-the-Market Sales Facility
30 déc. 2020 18h10 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced...
Medicenna Announces Oral Presentation at the 2nd Annual Glioblastoma Drug Development Summit
09 déc. 2020 07h00 HE
|
Medicenna Therapeutics Corp.
- Presentation taking place today, December 9, 2020 at 10:50 AM ET TORONTO and HOUSTON, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA...
Medicenna Hosting Key Opinion Leader Call on MDNA55 for the Treatment of Recurrent Glioblastoma Multiforme
02 déc. 2020 07h00 HE
|
Medicenna Therapeutics Corp.
- Call will take place on Friday, December 11, 2020 at 11:00 AM ET TORONTO and HOUSTON, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ:...
Medicenna to Participate in Upcoming December Investor Conferences
23 nov. 2020 07h30 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Announces Upcoming Oral Presentations at the 2020 Society for Neuro-Oncology Annual Meeting
18 nov. 2020 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Reports Second Quarter Fiscal 2021 Financial Results and Operational Highlights
13 nov. 2020 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA; TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna to Present at Upcoming Scientific and Investor Events in November
02 nov. 2020 07h30 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (Nasdaq: MDNA) (TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Presents Promising Preclinical Data on IL-2 and IL-13 Superkines at the EORTC-NCI-AACR Annual Meeting
26 oct. 2020 08h00 HE
|
Medicenna Therapeutics Corp.
-- Monotherapy and combination studies continue to demonstrate best-in-class potential of MDNA11 -- Bispecific IL-2/IL-13 Superkine demonstrates the potential to treat immunologically “cold” tumors ...
Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting
26 oct. 2020 07h00 HE
|
Medicenna Therapeutics Corp.
-- Amongst an all-comer population, a single treatment with MDNA55 resulted in at least 100% increase in both 12 month progression free survival (PFS-12 of 27% versus 2 to 10%) and 2-year survival...
Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual Meeting
19 oct. 2020 07h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today...